Supplementary 2: Overall JAK-inhibitor outcomes

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Ruxolitinib | | | | | | | | | | |
| Indication | Birth Outcomes | | | | | Congenital Malformation | Exposure Until | | | |
|  | Live Birth | Spontaneous Abortion | Still Birth | Ectopic Pregnancy | Elective Termination |  | First | Second | Third | Ongoing |
| RA | 80 | 40 | 0 | 0 | 17 | 3 | 129 | 2 | 1 | 0 |
|  | 58.4% | 29.2% | 0.0% | 0.0% | 12.4% | 3.8% | 97.7% | 1.5% | 0.8% | 0.0% |
| PsA | 7 | 1 | 0 | 1 | 2 | 0 | 10 | 0 | 0 | 1 |
|  | 63.6% | 9.1% | 0.0% | 9.1% | 18.2% | 0.0% | 90.9% | 0.0% | 0.0% | 9.1% |
| PsO | 19 | 1 | 0 | 0 | 10 | 0 | 36 | 0 | 0 | 0 |
|  | 63.3% | 3.3% | 0.0% | 0.0% | 33.3% | 0.0% | 100.0% | 0.0% | 0.0% | 0.0% |
| spondyloarthritis | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 |
|  | 100.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 100.0% | 0.0% | 0.0% |
| AD | 16 | 4 | 0 | 0 | 14 | 0 | 23 | 1 | 0 | 0 |
|  | 47.1% | 11.8% | 0.0% | 0.0% | 41.2% | 0.0% | 95.8% | 4.2% | 0.0% | 0.0% |
| UC | 19 | 3 | 0 | 0 | 5 | 0 | 27 | 0 | 0 | 2 |
|  | 70.4% | 11.1% | 0.0% | 0.0% | 18.5% | 0.0% | 93.1% | 0.0% | 0.0% | 6.9% |
| CD | 5 | 2 | 0 | 0 | 0 | 2 | 6 | 0 | 0 | 1 |
|  | 71.4% | 28.6% | 0.0% | 0.0% | 0.0% | 40.0% | 85.7% | 0.0% | 0.0% | 14.3% |
| SAPHO | 1 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 |
|  | 100.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 100.0% | 0.0% | 0.0% | 0.0% |
| RHL | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 1 |
|  | 0.0% | 0.0% | 0.0% | 0.0% | 100.0% | #DIV/0! | 0.0% | 0.0% | 0.0% | 100.0% |
| Myelofibrosis | 1 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 |
|  | 100.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 100.0% | 0.0% | 0.0% | 0.0% |
| AA | 1 | 2 | 0 | 0 | 2 | 0 | 0 | 0 | 0 | 0 |
|  | 20.0% | 40.0% | 0.0% | 0.0% | 40.0% | 0.0% | #DIV/0! | #DIV/0! | #DIV/0! | #DIV/0! |
| NR | 24 | 18 | 0 | 1 | 7 | 0 | 0 | 0 | 0 | 0 |
|  | 48.0% | 36.0% | 0.0% | 2.0% | 14.0% | 0.0% | #DIV/0! | #DIV/0! | #DIV/0! | #DIV/0! |
| Total | 174 | 71 | 0 | 2 | 58 | 5 | 233 | 4 | 1 | 5 |
| 305 | 57.0% | 23.3% | 0.0% | 0.7% | 19.0% | 2.9% | 95.9% | 1.6% | 0.4% | 2.1% |